Ochrona przed dezinformacją dotyczącą lenakapawiru wśród młodych kobiet w Gauteng, RPA (PROTECT-L) (PROTECT-L)
Ochrona przed dezinformacją dotyczącą lenakapawiru wśród młodych kobiet w Gautengu, RPA
Adolescent girls and young women (AGYW) in South Africa remain disproportionately affected by HIV, with prevalence among 15-24-year-olds at 9.4% in 2024 despite expanded access to condoms, HIV testing, and oral PrEP. While oral PrEP is effective, its reliance on daily adherence and regular follow-up has limited impact for many young women. Lenacapavir (LEN), the first long-acting injectable PrEP administered twice yearly, offers a promising alternative that could improve persistence and protection. However, LEN's potential may be undermined by misinformation, particularly around safety and trust, which has been shown in other HIV prevention contexts to reduce uptake and demand. Proactive strategies, such as psychological inoculation, are therefore needed to prebunk misinformation and support future LEN implementation among AGYW.
Primary objective: To compare changes in intentions to receive Lenacapavir following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.
Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about Lenacapavir in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Teniola Egbe, MPH, MBE
- Numer telefonu: 215-898-2939
- E-mail: tegbe@pennmedicine.upenn.edu
Kopia zapasowa kontaktu do badania
- Nazwa: Alison Buttenheim, PhD
- E-mail: butt@nursing.upenn.edu
Lokalizacje studiów
-
-
-
Johannesburg, Afryka Południowa
- Rekrutacyjny
- Health Economics and Epidemiology Research Office, University of the Witwatersrand
-
Kontakt:
- Candice Chetty-Makkan, PhD
- Numer telefonu: +27 (0) 10 001 7941
- E-mail: cchetty@heroza.org
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Female (cisgender or transgender)
- Age 18-29 years
- Self-reported history of sexual activity in the past 12 months
- Self-reported HIV-negative status or unknown HIV status at enrolment
- Willing and able to provide consent
- Able to read and understand English
Exclusion Criteria:
Unwilling or unable to provide consent for study participation.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Aktywny komparator: Control
Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study |
Participants enrolled in the control group will receive unrelated information on diabetes topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study |
|
Inny: Enhanced inoculation message
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impendingLlenacapavir misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime |
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending Lenacapavir misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Lenacapavir intention, at the end of the baseline assessment
Ramy czasowe: At the end of the baseline assessment
|
Intention to get the Lenacapavir, measured after inoculation intervention and misinformation exposure The intention to get Lenacapavir will be measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
At the end of the baseline assessment
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Lenacapavir intention, follow-up
Ramy czasowe: 2-4 weeks
|
Intention to get Lenacapavir, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
2-4 weeks
|
|
Recommend to friends, at the end of the baseline assessment
Ramy czasowe: At the end of the baseline assessment
|
Intention to recommend Lenacapavir to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
At the end of the baseline assessment
|
|
Recommend to friends, follow-up
Ramy czasowe: 2-4 weeks
|
Intention to recommend Lenacapavir to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
2-4 weeks
|
|
Credibility of inoculated exposure #1
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #2
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #3
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #4
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #5
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #6
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #7,follow-up
Ramy czasowe: 2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Credibility of inoculated exposure #8,follow-up
Ramy czasowe: 2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim ,for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Credibility of inoculated exposure #9,follow-up
Ramy czasowe: 2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Credibility of inoculated exposure #10,follow-up
Ramy czasowe: 2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #1
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #2
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #3
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #4
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #5
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #6
Ramy czasowe: At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #7,follow-up
Ramy czasowe: 2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #8,follow-up
Ramy czasowe: 2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #9,follow-up
Ramy czasowe: 2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #10,follow-up
Ramy czasowe: 2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Shareability of inoculated exposure #1
Ramy czasowe: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #2
Ramy czasowe: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #3
Ramy czasowe: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #4
Ramy czasowe: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #5
Ramy czasowe: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #6
Ramy czasowe: At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #7,follow-up
Ramy czasowe: 2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
|
Shareability of inoculated exposure #8,follow-up
Ramy czasowe: 2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
|
Shareability of inoculated exposure #9,follow-up
Ramy czasowe: 2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
|
Shareability of inoculated exposure #10,follow-up
Ramy czasowe: 2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 859478
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The investigators are still determining the data sharing plan and if we will be sharing IPD yet
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .